Human FRA‑1 Antibody

Name: Human FRA‑1 Antibody
Brand: R&D Systems
SKU: AF4935
Price: 479 USD
Availability: InStock

R&D Systems | Catalog # AF4935

Submit a review

Citations (3)

Product Documents

View Available Conjugates

100% Guarantee

Product Specifications
Scientific Data
Applications
Preparation & Storage
Calculators
Background
Product Documents
Specific Notices
Research Areas

Key Product Details

Validated by

Biological Validation

Species Reactivity

Validated:

Human

Cited:

Human, Mouse

Applications

Validated:

Immunohistochemistry, Western Blot

Cited:

Immunohistochemistry, Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG

View all FRA-1 Primary Antibodies »

Product Specifications

Immunogen

E. coli-derived recombinant human FRA-1
Gly146-Ala247
Accession # P15407

Specificity

Detects human and mouse FRA-1 in Western blots.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Scientific Data Images for Human FRA‑1 Antibody

Detection of Human FRA‑1 by Western Blot.

Western blot shows lysates of A172 human glioblastoma cell line untreated (-) or treated (+) with 100 ng/mL Recombinant Human EGF (Catalog # 236-EG) for 18 hours. PVDF membrane was probed with 0.2 µg/mL of Goat Anti-Human FRA-1 Polyclonal Antibody (Catalog # AF4935), followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). A specific band was detected for FRA-1 at approximately 45 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

FRA‑1 in Human Melanoma.

FRA-1 was detected in immersion fixed paraffin-embedded sections of human melanoma using Goat Anti-Human FRA-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4935) at 3 µg/mL overnight at 4 °C. Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to nuclei. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Applications for Human FRA‑1 Antibody

Application

Recommended Usage

Immunohistochemistry

5-15 µg/mL
Sample: Immersion fixed paraffin-embedded sections of human melanoma

Western Blot

0.2 µg/mL
Sample: A172 human glioblastoma cell line treated with Recombinant Human EGF (Catalog # 236-EG)

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Background: FRA-1

FRA-1 is a member of the leucine zipper Fos family of transcription factors. Fos family members have been associated with cellular proliferation, differentiation and transformation. In accordance with these findings, overexpression of FRA-1 correlates with a malignant phenotype in breast cancer. In lung epithelia cells, FRA-1 promotes motility, invasion, and anchorage independent growth. FRA-1 knock out mice rescued for the FRA-1 placental defect are viable but show reduced bone formation that may be due to a defect in the osteoblast differentiation.